Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.51 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.51 |
| ▸ | ACP1 | P24666 | 3/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.43 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | RXRG | P48443 | 1/20 | 0.43 |
| ▸ | BCL2 | P10415 | 1/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.43 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3039367 | 0.91 | LTA4H (0.59) | LTA4HPTPN1PTPN2ACP1FFAR1 | |
| SCHEMBL3039091 | 0.87 | LTA4H (0.67) | LTA4HPTPN1ACP1SMN1; SMN2SRD5A2 | |
| SCHEMBL3039090 | 0.85 | LTA4H (0.65) | LTA4HPTGER4SRD5A2PKM | |
| SCHEMBL30567407 | 0.81 | LTA4H (0.47) | LTA4HPTPN1PTPN2ACP1FFAR1 | |
| SCHEMBL3032189 | 0.81 | LTA4H (0.78) | LTA4HSRD5A2 | |
| SCHEMBL3040796 | 0.80 | FFAR1 (0.53) | LTA4HFFAR1 | |
| SCHEMBL3042625 | 0.80 | LTA4H (0.57) | LTA4HPTGER4 | |
| SCHEMBL3039708 | 0.79 | LTA4H (0.69) | LTA4HSRD5A2 | |
| SCHEMBL3045919 | 0.78 | LTA4H (0.60) | LTA4HTSHRPKM | |
| SCHEMBL3033373 | 0.77 | LTA4H (0.67) | LTA4HSRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1976828-B1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELTAXSYS INC (US) | 2016-12-21 | — | — | EP | claimed |
| US-7737145-B2 | Diamine derivatives as inhibitors of leukotriene A4 hydrolase | ESTRELLITA PHARMACEUTICALS, LLC (US) | 2010-06-15 | — | — | US | claimed |
| EP-1976828-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | Schering Aktiengesellschaft (DE) | 2008-10-08 | — | — | EP | claimed |
| WO-2007079078-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-07-12 | — | — | WO | claimed |
| US-20250296935-A1 | Diamine Derivatives as Inhibitors of Leukotriene A4 Hydrolase | CELLTAXIS LLC (US) | 2025-09-25 | — | — | US | disclosed |
| US-12173009-B2 | Diamine derivatives as inhibitors of leukotriene A4 hydrolase | CELLTAXIS, LLC (US) | 2024-12-24 | — | — | US | disclosed |
| US-20230250104-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELLTAXIS LLC (US) | 2023-08-10 | — | — | US | disclosed |
| US-11426399-B2 | Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase | ALKAHEST, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| US-20220226304-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | ALKAHEST, INC. | 2022-07-21 | — | — | US | disclosed |
| US-11344542-B2 | Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase | ALKAHEST, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-11267819-B2 | Diamine derivatives as inhibitors of leukotriene A4 hydrolase | Celltaxsis, LLC (US) | 2022-03-08 | — | — | US | disclosed |
| US-20200368220-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | ALKAHEST, INC. | 2020-11-26 | — | — | US | disclosed |
| US-20150080382-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | DOMAIN PARTNERS VIII, L.P. | 2015-03-19 | — | — | US | disclosed |
| US-8569303-B2 | Diamine derivatives as inhibitors of leukotriene A4 hydrolase | CELTAXSYS, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20130123243-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELTAXSYS, INC. | 2013-05-16 | — | — | US | disclosed |
| US-20100210630-A1 | Diamine Derivatives as Inhibitors of Leukotriene A4 Hydrolase | ESTRELLITA PHARMACEUTICALS, LLC | 2010-08-19 | — | — | US | disclosed |
| US-7737145-B2 | Diamine derivatives as inhibitors of leukotriene A4 hydrolase | ESTRELLITA PHARMACEUTICALS, LLC (US) | 2010-06-15 | — | — | US | disclosed |
| EP-1976828-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | Schering Aktiengesellschaft (DE) | 2008-10-08 | — | — | EP | disclosed |
| WO-2007079078-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-07-12 | — | — | WO | disclosed |
| US-20070155726-A1 | Diamine derivatives as inhibitors of leukotriene A4 hydrolase | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123243-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTB4R, LTC4S | LTA4H 1/4885PTPN1 3027/4885PTPN2 3604/4885 |
| US-11344542-B2 | Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase | LTA4H, LTB4R, LTC4S | LTA4H 1/4885PTPN1 4528/4885PTPN2 4638/4885 |
| US-12173009-B2 | Diamine derivatives as inhibitors of leukotriene A4 hydrolase | LTA4H, LTB4R, LTC4S | LTA4H 1/4885PTPN1 3027/4885PTPN2 3604/4885 |
| US-11426399-B2 | Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase | LTA4H, LTB4R, LTC4S | LTA4H 1/4885PTPN1 4528/4885PTPN2 4638/4885 |
| US-20150080382-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTB4R, LTC4S | LTA4H 1/4885PTPN1 3027/4885PTPN2 3604/4885 |
| US-20220226304-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | LTA4H, LTB4R, LTC4S | LTA4H 1/4885PTPN1 4528/4885PTPN2 4638/4885 |
| US-20250296935-A1 | Diamine Derivatives as Inhibitors of Leukotriene A4 Hydrolase | LTA4H, LTB4R, LTC4S | LTA4H 1/4885PTPN1 3027/4885PTPN2 3604/4885 |
| US-20070155726-A1 | Diamine derivatives as inhibitors of leukotriene A4 hydrolase | LTA4H, LTB4R, LTC4S | LTA4H 1/4885PTPN1 3027/4885PTPN2 3604/4885 |
| US-11267819-B2 | Diamine derivatives as inhibitors of leukotriene A4 hydrolase | LTA4H, LTB4R, LTC4S | LTA4H 1/4885PTPN1 3027/4885PTPN2 3604/4885 |
| US-20230250104-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTB4R, LTC4S | LTA4H 1/4885PTPN1 3027/4885PTPN2 3604/4885 |
| US-20100210630-A1 | Diamine Derivatives as Inhibitors of Leukotriene A4 Hydrolase | LTA4H, LTB4R, LTC4S | LTA4H 1/4885PTPN1 3027/4885PTPN2 3604/4885 |
| US-20200368220-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | LTA4H, LTB4R, LTC4S | LTA4H 1/4885PTPN1 4528/4885PTPN2 4638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.